Designing a First-in-Human Study of an Autologous CRISPR-Edited Hematopoietic Cell Therapy in Severe Sickle Cell Disease: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

A gene-edited cell therapy cannot be given in ascending doses to healthy volunteers: collection, conditioning, and engraftment make the intervention irreversible, and the dose that matters is the one that restores blood formation. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of an autologous CD34-positive hematopoietic cell product edited ex vivo with CRISPR-Cas9 at an erythroid-specific enhancer to raise fetal hemoglobin in adults with severe sickle cell disease. It proposes an open-label, single-arm study of about 12 participants at three transplant centers, enrolled sequentially after safety and engraftment review of the first participant, with a single infusion at a minimum of 3 million viable edited CD34-positive cells per kilogram as a planning assumption. Primary endpoints are safety and hematopoietic recovery through Month 12, with fetal hemoglobin, edited-cell persistence, and severe vaso-occlusive crisis frequency as secondary and exploratory measures, followed by risk-based long-term surveillance that FDA guidance suggests may extend to 15 years. The article explains why dose escalation is not used and why exposure is measured by engraftment and persistence and not by plasma concentration.Keywords: first-in-human; gene editing; CRISPR-Cas9; sickle cell disease; autologous cell therapy; fetal hemoglobin; long-term follow-up; Phase 1 protocol

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24426426
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Designing a First-in-Human Study of an Autologous CRISPR-Edited Hematopoietic Cell Therapy in Severe Sickle Cell Disease: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

Dorcas Koomson, Peivand Pirouzi, Gloria Anthonia Amoateng Agyemang
Zenodo (CERN European Organization for Nuclear Research)
Hemoglobinopathies and Related Disorders
article

Designing a First-in-Human Study of an Autologous CRISPR-Edited Hematopoietic Cell Therapy in Severe Sickle Cell Disease: Scientific and Regulatory Rationale and Phase 1 Protocol Synopsis

Dorcas Koomson, Peivand Pirouzi, Gloria Anthonia Amoateng Agyemang
article en

Abstract

A gene-edited cell therapy cannot be given in ascending doses to healthy volunteers: collection, conditioning, and engraftment make the intervention irreversible, and the dose that matters is the one that restores blood formation. This article develops the scientific and regulatory rationale and a complete protocol synopsis for a hypothetical first-in-human study of an autologous CD34-positive hematopoietic cell product edited ex vivo with CRISPR-Cas9 at an erythroid-specific enhancer to raise fetal hemoglobin in adults with severe sickle cell disease. It proposes an open-label, single-arm study of about 12 participants at three transplant centers, enrolled sequentially after safety and engraftment review of the first participant, with a single infusion at a minimum of 3 million viable edited CD34-positive cells per kilogram as a planning assumption. Primary endpoints are safety and hematopoietic recovery through Month 12, with fetal hemoglobin, edited-cell persistence, and severe vaso-occlusive crisis frequency as secondary and exploratory measures, followed by risk-based long-term surveillance that FDA guidance suggests may extend to 15 years. The article explains why dose escalation is not used and why exposure is measured by engraftment and persistence and not by plasma concentration.Keywords: first-in-human; gene editing; CRISPR-Cas9; sickle cell disease; autologous cell therapy; fetal hemoglobin; long-term follow-up; Phase 1 protocol

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Hemoglobinopathies and Related Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon